01.17.20
Civica Rx has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway. By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug shortages in the future.
This partnership has an initial seven-year term and represents a key component of Civica’s manufacturing strategy. By partnering with Thermo Fisher, Civica will begin to build its internal pipeline of medications for use in emergency and critical care in the U.S. To date, Civica has worked with multiple quality drug manufacturers that already have U.S. FDA approved manufacturing facilities and capacity to produce Civica labeled drugs in an effort to get shortage medications to market immediately.
“We are thrilled to enter into a partnership with a world class organization that is dedicated to helping Civica serve patients,” said Martin VanTrieste, president and chief executive officer, Civica. “The Thermo Fisher team is known for top manufacturing talent, supply reliability, product quality and innovation. We look forward to working with them to develop and produce Civica medicines.”
Mike Shafer, president of Thermo Fisher’s Pharma Services business, said, “We thank Civica for their confidence in our team and capabilities and welcome this opportunity to work with them to help mitigate the risk of drug shortages in the U.S.. Together we will be able to deliver medicines to the market sooner to the patients who are waiting.”
Initially the Thermo Fisher collaboration will focus on nine critical medications that have been in short supply or where the drug supply chain is fragile because there are too few manufacturers making these drugs. Civica’s hospital-led drug selection and medical trends advisory committees helped prioritize these medications for Civica’s Research & Development efforts.
This partnership has an initial seven-year term and represents a key component of Civica’s manufacturing strategy. By partnering with Thermo Fisher, Civica will begin to build its internal pipeline of medications for use in emergency and critical care in the U.S. To date, Civica has worked with multiple quality drug manufacturers that already have U.S. FDA approved manufacturing facilities and capacity to produce Civica labeled drugs in an effort to get shortage medications to market immediately.
“We are thrilled to enter into a partnership with a world class organization that is dedicated to helping Civica serve patients,” said Martin VanTrieste, president and chief executive officer, Civica. “The Thermo Fisher team is known for top manufacturing talent, supply reliability, product quality and innovation. We look forward to working with them to develop and produce Civica medicines.”
Mike Shafer, president of Thermo Fisher’s Pharma Services business, said, “We thank Civica for their confidence in our team and capabilities and welcome this opportunity to work with them to help mitigate the risk of drug shortages in the U.S.. Together we will be able to deliver medicines to the market sooner to the patients who are waiting.”
Initially the Thermo Fisher collaboration will focus on nine critical medications that have been in short supply or where the drug supply chain is fragile because there are too few manufacturers making these drugs. Civica’s hospital-led drug selection and medical trends advisory committees helped prioritize these medications for Civica’s Research & Development efforts.
